Helmut Butzkueven

Sitert av

	Alle	Siden 2019
Sitater	26486	15096
h-indeks	74	55
i10-indeks	258	222

2800

1400

700

2100

20042005200620072008200920102011201220132014201520162017201820192020202120222023202479 97 150 199 244 298 472 516 758 1015 1103 1386 1508 1469 1657 1879 2359 2771 2705 2714 2592

Offentlig tilgang

Vis alle

171 artikler

32 artikler

tilgjengelige

ikke tilgjengelige

Basert på finansieringsmandater

Medforfattere

Anneke Van Der WaltAssociate Professor, Central Clinical School, Monash UniversityVerifisert e-postadresse på monash.edu
Bruce V Taylormenzies Research Institute Tasmania University of TasmaniaVerifisert e-postadresse på utas.edu.au
maria trojanoDipartimento di Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Università degli StudiVerifisert e-postadresse på uniba.it
Jeannette Lechner-ScottHunter Medical Research InstituteVerifisert e-postadresse på health.nsw.gov.au
Associate Professor Vilija G. JokubaitisNeuroimmunology Genomics and Prognostics Group Head, Monash UniversityVerifisert e-postadresse på monash.edu
Jim StankovichStatistician, Primary Health TasmaniaVerifisert e-postadresse på primaryhealthtas.com.au
Michael BarnettThe University of Sydney / Brain and Mind CentreVerifisert e-postadresse på sydney.edu.au
Ludwig KapposUniversity of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)Verifisert e-postadresse på uhbs.ch
Scott KolbeMonash UniversityVerifisert e-postadresse på monash.edu
Mastura MonifAssociate Professor, Dept of Neurosciences, Monash University), Neurologist (AlfredVerifisert e-postadresse på monash.edu
Gary EganMonash Biomedical Imaging, Monash UniversityVerifisert e-postadresse på monash.edu
Gavin GiovannoniQueen Mary University of LondonVerifisert e-postadresse på giovannoni.net
Maria Pia SormaniUniversity of GenoaVerifisert e-postadresse på unige.it
Ingrid van der MeiMenzies Institute for Medical Research, University of TasmaniaVerifisert e-postadresse på utas.edu.au
Justin Paul RubioAssociate Prof of Human Genetics, The Florey Institute of Neuroscience andVerifisert e-postadresse på unimelb.edu.au
Terence J. O'BrienThe Department of Neuroscience, Monash University; Department of Neurology, Alfred HealthVerifisert e-postadresse på monash.edu
Mark SleeCollege of Medicine and Public Health, Flinders University of South AustraliaVerifisert e-postadresse på flinders.edu.au
Melanie BahloTheme Leader, Healthy Development and Ageing, The Walter and Eliza Hall Institute ofVerifisert e-postadresse på wehi.edu.au
Simon BroadleyProfessor of Neurology, Griffith UniversityVerifisert e-postadresse på griffith.edu.au
Andrew EvansReta Lila Weston Institute and the Royal Melbourne HospitalVerifisert e-postadresse på pobox.com

Følg

Helmut Butzkueven

MSNI Research Group, Dept of Neuroscience, School of Translational Medicine, Monash University

Verifisert e-postadresse på monash.edu

Multiple Sclerosis and Neuroimmunology


Tittel Sorter etter sitater Sorter etter år Sorter etter tittel	Sitert av Sitert av	År
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 (7359), 214-219, 2011	3050	2011
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ... Nature genetics 45 (11), 1353-1360, 2013	1371	2013
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005	1103	2005
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018	1044	2018
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, R Simmons, ... Bmj 327 (7410), 316, 2003	762	2003
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability CL Martin, BA Phillips, TJ Kilpatrick, H Butzkueven, N Tubridy, ... Multiple Sclerosis Journal 12 (5), 620-628, 2006	742	2006
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination S Ramanathan, S Mohammad, E Tantsis, TK Nguyen, V Merheb, ... Journal of Neurology, Neurosurgery & Psychiatry 89 (2), 127-137, 2018	554	2018
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 Data analysis: Bahlo Melanie 2 Brown Matthew A 6 7 Browning Brian L 20 ... Nature genetics 41 (7), 824-828, 2009	547	2009
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019	525	2019
Brain health: time matters in multiple sclerosis G Giovannoni, H Butzkueven, S Dhib-Jalbut, J Hobart, G Kobelt, G Pepper, ... Multiple sclerosis and related disorders 9, S5-S48, 2016	523	2016
Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016	445	2016
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, BV Taylor, T Kilpatrick, ... Journal of neurology 254, 581-590, 2007	443	2007
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci NA Patsopoulos, ... Annals of neurology 70 (6), 897-912, 2011	369	2011
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020	349	2020
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival H Butzkueven, JG Zhang, M Soilu-Hanninen, H Hochrein, F Chionh, ... Nature medicine 8 (6), 613-619, 2002	327	2002
Geographical variations in sex ratio trends over time in multiple sclerosis M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ... PloS one 7 (10), e48078, 2012	278	2012
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ... The Lancet Neurology 16 (3), 189-199, 2017	269	2017
Onset seizures independently predict poor outcome after subarachnoid hemorrhage H Butzkueven, AH Evans, A Pitman, C Leopold, DJ Jolley, AH Kaye, ... Neurology 55 (9), 1315-1320, 2000	259	2000
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis MS Stein, Y Liu, OM Gray, JE Baker, SC Kolbe, MR Ditchfield, GF Egan, ... Neurology 77 (17), 1611-1618, 2011	241	2011
Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis S Simpson-Yap, E De Brouwer, T Kalincik, N Rijke, JA Hillert, C Walton, ... Neurology 97 (19), e1870-e1885, 2021	240	2021

Systemet kan ikke utføre handlingen. Prøv på nytt senere.

Artikler 1–20

Sitater per år

Duplikatsitater

Sammenslåtte sitater

Legg til medforfattereMedforfattere

Følg

Sitert av

Medforfattere